Abbott Laboratories (Abbott Laboratories) Cash-to-Debt : 0.47 (As of Dec. 2023)

View and export this data going back to 1949. Start your Free Trial

What is Abbott Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Abbott Laboratories's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.47.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Abbott Laboratories couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Abbott Laboratories's Cash-to-Debt or its related term are showing as below:

ABT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 0.5 Max: 0.85
Current: 0.47

During the past 13 years, Abbott Laboratories's highest Cash to Debt Ratio was 0.85. The lowest was 0.21. And the median was 0.50.

ABT's Cash-to-Debt is ranked worse than
74.01% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs ABT: 0.47

Abbott Laboratories Cash-to-Debt Historical Data

The historical data trend for Abbott Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Abbott Laboratories Cash-to-Debt Chart

Abbott Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.22

0.36

0.54

0.57

0.47

Abbott Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.56	0.48	0.45	0.47	N/A

Competitive Comparison of Abbott Laboratories's Cash-to-Debt

For the Medical Devices subindustry, Abbott Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbott Laboratories's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Cash-to-Debt falls into.

Abbott Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Abbott Laboratories's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7279	/	(1080	+	14548)
	=	0.47

Abbott Laboratories's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7279	/	(1080	+	14548)
	=	0.47

Abbott Laboratories (NYSE:ABT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Abbott Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbott Laboratories (Abbott Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ABT:Mexico 0Q15:UK ABL:Germany ABL:Germany ABL:Germany ABL:Germany ABT:Chile ABT:Switzerland ABTT34:Brazil ABT:Austria ABT:Argentina

Address

100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website

https://www.abbottinvestor.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Executives

Andrea F Wainer	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr.	officer: VICE PRESIDENT	C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman	director	3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone	officer: EXECUTIVE VICE PRESIDENT	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau	officer: Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady	director	50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive	officer: Senior Vice President	100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt	officer: Executive Vice President	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck	officer: Vice President, Controller	100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092